Primary prevention: Do the very elderly require a different approach?

Trends in Cardiovascular Medicine

Volumn 25, Issue 3, 2015, Pages 228-239

  Schwartz, Janice B ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Jewish Home of San Francisco   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ATRIOVENTRICULAR BLOCK; BLEEDING; BRAIN HEMORRHAGE; CONSTIPATION; EXERCISE; GERIATRIC DISORDER; HUMAN; HYPERTENSION; LIFE EXPECTANCY; LIFESPAN; MUSCULOSKELETAL PAIN; MYOPATHY; ORTHOSTATIC HYPOTENSION; PATIENT PREFERENCE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; UROGENITAL TRACT DISEASE; VERY ELDERLY; CARDIOVASCULAR DISEASES; DEMENTIA; HYPERCHOLESTEROLEMIA; STROKE;

AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DEMENTIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; STROKE;

EID: 84925270003     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.10.010     Document Type: Review

References (77)

1. Lee S., Lindquist K., Segal M., Covinsky K. Development and validation of a prognostic index for 4-year mortality in older adults. J Am Med Assoc 2006, 295:801-808.
2. Cruz M., Covinsky K., Widera E.W., Stijacic-Cenzer M.A., Lee S.L. Predicting 10-year mortality for older adults. J Am Med Assoc 2013, 309:874-876.
3. Cho H., Klabunde C.N., Yabroff K.R., Wang Z., Meekins A., Lansdorp-Vogelaar I., et al. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med 2013, 159:667-676.
4. Keeler E., Guralnik J.M., Tian H., Wallace R.B., Reuben D.B. The impact of functional status on life expectancy in older persons. J Gerontol A Biol Sci Med Sci 2010, 65:727-733.
5. Salpeter S.R., Luo E.J., Malter D.S., Stuart B. Systematic review of noncancer presentations with a median survival of 6 months or less. Am J Med 2012, 125:e1-e16.
6. Coope J., Warrender T. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986, 293:1145-1152.
7. Dahlof B., Lindholm L., Hansson L., Schersten B., Ekbom T., Wester P.-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338:1281-1285.
8. SHEP.Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991, 265:3255-3264.
9. Staessen J., Fagard R., Thijus L., Celis H., Arabidze G.G., Birkenhager W.H., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757-764.
10. Beckett N., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887-1898.
11. Liu L., Wang J.G., Gong L., Liu G., Staessen J.A. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J Hypertens 1998, 16:1823-1829.
12. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
13. Trenkwalder P., Elmfeldt D., Hofman A., Lithell H., Olofsson B., Papademetriou V., et al. The Study on COgnition and Prognosis in the Elderly (SCOPE)-major CV events and stroke in subgroups of patients. Blood Press 2005, 14:31-37.
14. JATOS.Study Group Principal results of the Japanese Trial to Assess Optimal Systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008, 31:2115-2127.
15. Ogihara T., Saruta T., Rakugi H., Matsuoka H., Shimamoto K., Shimada K., et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010, 56:196-202.
16. Verdecchia P., Staessen J.A., Angeli F., de Simone G., Achilli A., Ganau A., et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009, 374:525-533. [Erratum].
17. Reboldi G., Angeli F., de Simone G., Staessen J.A., Verdecchia P. Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension 2014, 63:475-482.
18. Jamerson K., Weber M., Bakris G., Dahlof B., Pitt B., Shi V., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
19. Ambrosius W., Sink K.M., Foy C.G., Berlowitz D.R., Cheung A.K., Cushman W.C., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014, [pii: 1740774514537404, Epub ahead of print].
20. McGuinness B., Todd S., Passmore P., Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009, 4:CD004034. http://dx.doi.org/10.1002/14651858.CD004034.pub3.
21. Marpillat L., Macquin-Mavier I., Tropeano A.I., Bachoud-Levi A., Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013, 6:1073-1082.
22. Kennelly S.P., Lawlor B.A., Kenny R.A. Blood pressure and dementia-a comprehensive review. Ther Adv Neurol Disord 2009, 2:241-260.
23. Krakoff L.R., Gillespie R.L., Ferdinand K.C., Fergus I.V., Akinboboye O., Williams K.A., et al. 2014 Hypertension recommendations from the Eighth Joint National Committee Panel Members raise concerns for elderly black and female populations. J Am Coll Cardiol 2014, 64:394-402.
24. James P., Oparil S., Carter B., Cushman W., Dennison-Himmelfarb C., Joel Handler J., et al. Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth Joint National Committee (JNC 8). J Am Med Assoc 2014, 311:507-520.
25. Hypertension without compelling indications: 2014 CHEP recommendations. Hypertension Canada. [accessed 24.07.14]. http://www.hypertension.ca/en/chep.
26. National Institute for Health and Clinical Excellence. Hypertension, ; 2014 [accessed 24.07.14]. http://pathways.nice.org.uk/pathways/hypertension.
27. Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34:2159-2219.
28. Steinman M.A., Miao Y., Boscardin W., Komaiko K.D.R., Schwartz J.B. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med 2014, 29(10):1379-1386.
29. Butt D.A., Mamdani M., Austin P.C., Tu K., Gomes T., Glazier R.H. The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 2013, 24:2649-2657.
30. Tinetti M., Han L., Lee D., McAvay G., Peduzzi P., Gross C., et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. J Am Med Assoc Intern Med 2014, 174:588-595.
31. Butt D.A., Mamdani M., Austin P.C., Tu K., Gomes T., Glazier R.H. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med 2012, 1739-1744.
32. Aronow W.S., Fleg J.L., Pepine C.J., Artinian N.T., Bakris G., Brown A.S., et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2011, 57:2037-2114.
33. Amerenco P., Bogousslavsky J., Callahan J., Goldstein L., Hennerici M., Rudolph A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Eng J Med 2006, 355:549-559.
34. Fihn S.D., Gardin J.M., Abrams J., Berra K., Blankenship J.C., Dallas A.P., et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012, 126(25):e354-471.
35. Fraker T., Fihn S. Writing on behalf of the 2002 Chronic Stable Angina Writing Committee. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/Amerian Heart Association Task Force on Practice guidelines writing group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 2007, 116:2762-2772.
36. Saverese G., Gotto A.M., Paolillo S., D[U+05F3]Amore C., Losco T., Musella F., et al. Benefits of statins in elderly subjects without established cardiovascular disease. J Am Coll Cardiol 2013, 62:2090-2099.
37. Sigurdsson A. Benefits of statins in healthy elderly subjects. What is the number needed to treat?. J Am Coll Cardiol 2014, 63:2302.
38. Savarese G., Perrone-Filardi P. Benefits of statins in healthy eldelry subjects. What is the number needed to treat?. J Am Coll Cardiol 2014, 63:2303.
39. Taylor F, Huffman M, Macedo A, Moore T, Burke M, Smith G, et al. Statins for the primary prevention of cardiovascular disease. The Cochrane Collaboration John Wiley & Sons, Ltd, ; 2013. http://thecochranelibrary.com.
40. Cholesterol Treatment Trialist[U+05F3] (CTT) Collaboration The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
41. Morris P.B., Ballantyne C.M., Birtcher K.K., Dunn S.P., Urbina E.M. Review of clinical practice guidleines for hte management of LDL-related risk. J Am Coll Cardiol 2014, 64:196-206.
42. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 Pt B):2889-2934.
43. Ridker P., Buring J., Rifai N., Cook N. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women the reynolds risk score. J Am Med Assoc 2007, 297:611-619.
44. Anderson T.J., Grégoire J., Hegele R.A., Couture P., Mancini J., McPherson R., et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
45. JBS3 Joint British Societies[U+05F3] consensus recommendations for the prevention of cardiovascular diseases (JBS3). Heart 2014, 100:ii1-ii67.
46. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG181), ; 2014. http://www.nice.org.uk/guidance/CG181.
47. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO Study. Cardiovasc Drugs Ther 2005, 19:403-414.
48. Buettner C., Rippberger M.J., Smith J.K., Leveille S.G., Davis R.B., Mittleman M.A. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012, 125:176-182.
49. Guyton J.R., Bays H.E., Grundy S.M., Jacobson T.A. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidology 2014, 8:S72-S81.
50. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
51. Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 2011, 305:2556-2564.
52. Desai C., Martin S., Blumenthal R.S. Non-cardiovascular effects associated with statins. Br Med J 2014, 349:g3743. 10.1136/bmj.g3743.
53. Padala K.P., Padala P.R., McNeilly D.P., Geske J.A., Sullivan D.H., Potter J.F. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer[U+05F3]s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012, 10:296-302.
54. de Langen J.J., van Puijenbroek E.P. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. Neth J Med 2006, 64:334-338.
55. Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C.
56. Fried T., Tinetti M., Towle V., O'Leary J., Iannone L. Effects of benefits and harms on older persons[U+05F3] willingness to take medication for primary cardiovascular prevention. Arch Intern Med 2011, 171:923-928.
57. Eckel R.H., Jakicic J.M., Ard J.D., Hubbard V.S., de Jesus J.M., Lee I.-M., et al. 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 63(25 Pt B):2960-2984.
58. Leveille S.G., Guralnik J.M., Ferrucci L., Langlois J.A. Aging successfully until death in old age: opportunities for increasing active life expectancy. Am J Epidemiol 1999, 149:654-664.
59. Blair S.N., Kohl H.W., Barlow C.E., Paffenbarger R.S., Gibbons L.W., Macera C.A. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. J Am Med Assoc 1995, 273:1093-1098.
60. Shortreed S.M., Peeters A., Forbes A.B. Estimating the effect of long-term physical activity on cardiovascular disease and mortality: evidence from the Framingham Heart Study. Heart 2013, 99:649-654.
61. Tremblay M.S., Warburton D.E.R., Janssen I., Paterson D.H., Latimer A.E., Rhodes R.E., et al. New Canadian physical activity guidelines. Appl Physiol Nutr Metab 2011, 36:36-46.
62. Halvorsen S., Andreotti F., ten Berg J.M., Cattaneo M., Coccheri S., Marchioli R., et al. Aspirin therapy in primary cardiovascular disease prevention a position paper of the European Society of Cardiology Working Group on Thrombosis. J Am Coll Cardiol 2014, 64:319-327.
63. Sutcliffe P., Connock M., Gurung T., Freeman K., Johnson S., Ngianga-Bakwin K., et al. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One 2013, 8:e81970.
64. Rothwell P.M., Price J.F., Fowkes F.G., Zanchetti A., Roncaglioni M.C., Tognoni G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379:1602-1612.
65. Amery A., Birkenhäger W., Brixko P., Bulpitt C.J., Clement D., Deruyttere M., et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985, 1:1349-1354.
66. Forette F., Seux M.-L., Staessen J.A., Lutgarde T., Babarskience M.-R., Babeanu S., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002, 162:2046-2052.
67. Gong L., Zwang W., Zhu Y. Shanghai trial of nifedipine in the elderly. Seventh European Meeting on Hypertension 1995.
68. Kirkman M.S., Briscoe V.J., Clark N., Florez H., Haas L.B., Halter J.B., et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012, 60:2342-2356.
69. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. the JNC 7 report. J Am Med Assoc 2003, 289:2560-2572.
70. Weber M.A., Schiffrin E.L., White W.B., Mann S., Lindholm L.H., Kenerson J.G., et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 2014, 16:14-26.
71. Canadian Hypertension Education Program (CHEP) 2014 Recommendations. http://www.hypertension.ca/en/chep.
72. Ridker P., Pradhan A., MacFadyen J., Libby P., Glynn R. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
73. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
74. Downs J., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998, 279:1615-1622.
75. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Am Med Assoc 2002, 288:2998-3007. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
76. Sever P., Dahlof B., Poulter N., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
77. Shepherd J., Blauw G., Murphy M., Bollen E., Buckley B., Cobbe S., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360:1623-1630.